Analysts who follow SAB Biotherapeutics Inc (SABS) on average expect it to rise 394.71% over the next twelve months. Those same analysts give the stock an average rating of Strong Buy.
That average rating earns SAB Biotherapeutics Inc an Analyst Ranking of 73, which means it ranks higher than 73 of stocks, based on data compiled by InvestorsObserver.
Wall Street analysts are rating SABS a Strong Buy today. Find out what this means to you and get the rest of the rankings on SABS!
Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions before a quarterly report that could be worse than expected.
InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.
What's Happening With SAB Biotherapeutics Inc Stock Today?
SAB Biotherapeutics Inc (SABS) stock is trading at $3.31 as of 10:59 AM on Monday, Apr 4, a decline of -$0.15, or -4.34% from the previous closing price of $3.46. The stock has traded between $3.28 and $3.55 so far today. Volume today is light. So far 99,535 shares have traded compared to average volume of 384,516 shares.
Click Here to get the full Stock Report for SAB Biotherapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
